Search

Displaying results 1431 - 1440 of 4207 in total
  1. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.

  2. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  3. Drug

    Sodium stibogluconate

    go.drugbank.com/drugs/DB05630
    ApprovedInvestigational

    Sodium stibogluconate is sold in the UK as Pentostam (manufactured by GlaxoSmithKline). … Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials.

  4. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.

  5. Drug

    Pramocaine

    go.drugbank.com/drugs/DB09345
    Approved

    Pramocaine is available by itself and in combination with other medications in various topical preparations. … It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation.

  6. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.

  7. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.

  8. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.

  9. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout

  10. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024.